证券代码：603538 证券简称：美诺华 公告编号：2025-096 ? 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 一、 召开会议的基本情况 （一）股东大会类型和届次 转债代码:113618 转债简称:美诺转债 宁波美诺华药业股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 股东大会召开日期：2025年9月11日 （二）股东大会召集人：董事会 （三）投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相 结合的方式 （四）现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 月 11 日 14 点 00 分 召开地点：浙江省宁波市高新区扬帆路 999 弄研发园 B1 号楼 12A 层 1 号会 议室 （五）网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 9 月 11 日 至2025 年 9 月 11 日 采用上海证券交易所网络投票系统 ...

Core Viewpoint - Ningbo Meinuohua Pharmaceutical Co., Ltd. plans to abolish its supervisory board and amend its articles of association, transferring the supervisory responsibilities to the audit committee of the board of directors, pending approval from the shareholders' meeting [1][2]. Group 1: Company Structure Changes - The company has passed a resolution to abolish the supervisory board and amend the articles of association in accordance with relevant laws and regulations [1]. - The supervisory responsibilities defined in the Company Law will be assumed by the audit committee after the amendments are approved [1][2]. - The current supervisory board will continue to fulfill its duties until the new articles of association come into effect [1]. Group 2: Amendments to Articles of Association - The amendments include changes to the terminology, such as replacing "shareholders' meeting" with "shareholders' assembly" [2]. - The registered capital of the company remains at RMB 21 million, and the total number of shares is 219,822,861, all of which are ordinary shares [2]. - The amendments also clarify the roles of the legal representative and the responsibilities of the board of directors and senior management [2][4]. Group 3: Governance and Compliance - The company emphasizes the need for compliance with laws and regulations in its governance structure, ensuring that the rights and obligations of shareholders are clearly defined [2][18]. - The articles of association will serve as a binding document for the company, shareholders, directors, and senior management, allowing for legal actions among these parties [2][18]. - The company will ensure that any financial assistance provided for share purchases will not exceed 10% of the total issued capital [2][8].

| 开始投产。 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | (二)募投项目先期投入及置换情况 | | | | | | | | | 本公司不存在募投项目先期投入及置换情况。 | | | | | | | | | (三)用闲置募集资金暂时补充流动资金情况 | | | | | | | | | 未发生使用闲置募集资金暂时补充流动资金的情况。 | | | | | | | | | (四) 对闲置募集资金进行现金管理，投资相关产品情况 | | | | | | | | | 公司分别于 2021 年 4 月 16 日、2021 年 5 月 | 12 日召开第三届董事会第二十 | | | | | | | | 七次会议和 2020 年年度股东大会，审议通过了《关于使用闲置募集资金进行现 | | | | | | | | | 金管理的议案》，同意在确保不影响募集资金投资项目建设和募集资金使用的情 | | | | | | | | | 50,000 万元的 况下，公司（包括控股子公司）使用单日最高余额不超过人民币 | | | | | | | | | ...

Summary of Key Points Core Viewpoint Ningbo Meinuo Pharmaceutical Co., Ltd. has reported on the status of its fundraising activities, detailing the amount raised, its usage, and the management of the funds as of June 30, 2025. The report highlights the company's commitment to regulatory compliance and effective fund management. Fundraising Basic Situation - The company raised a total of RMB 512,697,629.67 through the issuance of 5.2 million convertible bonds, with all funds received by January 20, 2021 [1]. - As of June 30, 2025, the net amount of actual raised funds was RMB 512,697,629.67, with RMB 120,013,509.22 allocated to supplement working capital [1][2]. Fund Usage and Balance - The company has utilized RMB 262,892,455.63 for the high-end formulation project and has also engaged in cash management with idle funds, generating a total of RMB 390.4 million in returns from investments [1][2]. - The total amount of idle funds invested in cash management reached RMB 29 million, with RMB 17 million redeemed during the reporting period [2][3]. Fund Management Situation - The company has established a dedicated account storage system for the raised funds, ensuring compliance with relevant regulations [1][2]. - As of June 30, 2025, the balance in the dedicated accounts totaled RMB 20,183,440.32, with specific accounts allocated for different projects [1][2]. Semi-Annual Fund Usage - The company has not experienced any delays in the planned progress of its fundraising investment projects, and there have been no significant changes in the feasibility of the projects [2][3]. - The high-end formulation project is expected to be completed by July 2025, with ongoing evaluations and adjustments to project timelines as necessary [3][4]. Changes in Fund Investment Projects - The company has approved changes to the allocation of funds, redirecting RMB 13,834.70 million from the high-end formulation project to the 734-ton pharmaceutical raw material project [4][5]. - There have been no instances of transferring or replacing the investment projects with external parties [4][5]. Issues in Fund Usage and Disclosure - The company has reported no significant issues in the usage and disclosure of the raised funds, maintaining transparency and compliance with regulatory requirements [4][5].

Core Points - The document outlines the code of conduct for the board of directors and senior management of Ningbo Meinuo Pharmaceutical Co., Ltd, aiming to standardize behavior and enhance corporate governance [1][2][3] Group 1: General Principles - The code is established to ensure compliance with laws, regulations, and the company's articles of association, emphasizing the importance of loyalty and diligence in fulfilling duties [1] - Directors and senior management are required to protect the interests of the company and all shareholders, maintain confidentiality, and avoid conflicts of interest [1][2] Group 2: Duties of Directors and Senior Management - Directors must treat all shareholders fairly, safeguard company assets, and not exploit their positions for personal gain [2][3] - They are obligated to attend board meetings personally or appoint a trusted representative with clear instructions, ensuring accountability [4][5] Group 3: Independent Directors - Independent directors must act independently and fairly, focusing on protecting the interests of minority shareholders and ensuring compliance with regulations [2][3] Group 4: Decision-Making and Reporting - Directors are required to thoroughly review materials before making decisions, ensuring that they understand the implications and risks involved [3][4] - They must report any significant changes or risks that could affect the implementation of board resolutions [5][6] Group 5: Financial Responsibilities - The financial officer is directly responsible for the preparation and disclosure of financial reports, ensuring the company's financial independence and integrity [7][8] - Any irregularities or potential violations must be reported to the board promptly [8][9] Group 6: Appointment and Resignation of Directors - Directors are elected for a term not exceeding three years and can be re-elected, with specific conditions under which they may be disqualified from serving [10][11] - Resignation procedures are outlined, ensuring that the board maintains its required composition [12][13]

Core Points - The company has established a separate voting counting and disclosure mechanism for minority investors during shareholder meetings to ensure their rights are protected [1][2] - The definition of minority investors excludes company directors, senior management, and shareholders holding more than 5% of the company's shares [1] - Specific significant matters that require separate counting of votes from minority investors include the nomination of independent directors, hiring or firing of accounting firms, changes in accounting policies, and major asset restructuring plans [1][2] Voting Procedures - The company will adopt a combination of on-site and online voting methods for counting votes from minority investors, with the first valid vote being considered [4] - During shareholder meetings, the company must separately register the attendance and voting rights of minority investors [5] - The results of the votes from minority investors will be specifically highlighted in the meeting records and resolutions [5] Information Disclosure - The company must provide specific details regarding the voting matters, voting methods, and online voting procedures in the meeting notifications and materials [6] - The announcement of the shareholder meeting resolutions must include the number of minority investors, their voting rights, and the proportion of their votes [6] Miscellaneous - If any provisions of this mechanism conflict with national laws or the company's articles of association, the latter will prevail [7] - The board of directors is responsible for formulating, amending, and interpreting this mechanism, which will take effect upon approval [7]

Group 1 - The company achieved operating revenue of 677 million yuan, representing a year-on-year growth of 11.42% [1] - The net profit attributable to shareholders of the listed company was 49.06 million yuan, showing a significant year-on-year increase of 158.97% [1] - The net profit attributable to shareholders of the listed company, after deducting non-recurring gains and losses, was 36.75 million yuan, reflecting a year-on-year growth of 86.98% [1] - The basic earnings per share were 0.22 yuan [1]

转债代码:113618 转债简称:美诺转债 证券代码：603538 证券简称：美诺华 公告编号：2025-096 宁波美诺华药业股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东大会召开日期：2025年9月11日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 一、 召开会议的基本情况 （一）股东大会类型和届次 2025年第一次临时股东大会 （二）股东大会召集人：董事会 （三）投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相 结合的方式 （四）现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 月 11 日 14 点 00 分 召开地点：浙江省宁波市高新区扬帆路 999 弄研发园 B1 号楼 12A 层 1 号会 议室 （五）网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 9 月 11 日 至2025 年 9 月 11 日 采用上海 ...

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-092 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 第五届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 表决结果：同意 3 票，反对 0 票，弃权 0 票。 1 （二）审议通过《2025 年半年度募集资金存放与实际使用情况的专项报告》 具体内容详见公司于上海证券交易所网（www.sse.com.cn）等指定信息披露 媒体同日披露的《2025 年半年度募集资金存放与实际使用情况的专项报告》。 监事会审核并发表如下意见：公司 2025 年半年度募集资金存放与实际使用 情况符合《上市公司募集资金监管规则》等相关法律法规、规章及其他规范性文 件的规定，公司对募集资金进行了专户存储和专项使用。募集资金存放与实际使 用情况与公司披露情况一致，不存在变相改变募集资金用途和损害股东利益的情 况，不存在违规使用募集资金的情况。 宁波 ...

一、董事会会议召开情况 第五届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-091 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 宁波美诺华药业股份有限公司（以下简称"公司"）于 2025 年 8 月 15 日以 书面、电子邮件等方式向公司全体董事发出召开第五届董事会第十六次会议的通 知和会议材料。2025 年 8 月 26 日，公司第五届董事会第十六次会议在公司会议 室以现场结合通讯表决方式召开。本次会议由姚成志先生主持，会议应出席董事 5 名，实际出席董事 5 名。公司监事、高级管理人员列席了会议。本次会议的召 集和召开符合《中华人民共和国公司法》等有关法律法规及《公司章程》《董事 会议事规则》的规定。 二、董事会会议审议情况 （一）审议通过《2025 年半年度报告及摘要》 具体内容详见公司于上海证券交易所网（www.sse.com.c ...